HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 25, No. 12, December 2021 – The Future of Us — Transforming Healthcare With Intelligent Machines       » Better Targeted Leukaemia Treatment With New Ferritin-Based Nanomedicine       » Manufacturing Chiral Medicine With New Cobalt-Based Catalyst       » SMART Develops 10-Minute Test for Detection of COVID Immunity       » From Plastics to Plants: Transforming Bio-Based Polymers into Fertilisers       » Creating Solar Cells and Glass From Wood and a Billion Tons of Biowaste      
Vol 21, No. 01, January 2017   |   Issue PDF view/purchase
EDITOR'S LETTER
We all know human beings breathe to stay alive. However, how often are we consciously mindful of how important a pair of healthy lungs are? What would happen if our lungs malfunction because of growing cancer cells?

In this APBN January 2017 issue, we will explore several treatment options for lung diseases and lung cancer:

At the IASLC 17th World Conference on Lung Cancer (WCLC), researchers presented their clinical trials that showed the promising progress of immunotherapy in lung cancer treatment. For instance, data from the KEYNOTE-024 trial showed that patients who received immunotherapy, pembrolizumab, are having a better quality of life than those that received chemotherapy.

Chronic Obstructive Pulmonary Disease (COPD) typically affects patients above the age of 50 and its main cause is smoking. APBN interviewed Professor Norbert Berend, an expert in respiratory research, who talked about Salford Lung Study (SLS). Sponsored by GSK, SLS was conducted to explore the effectiveness and safety of Relvar®Ellipta® in COPD patients in a real-life setting. You can check out this article in the Features section, as well as find out more about COPD, its difference from asthma, and available treatments.

In Singapore, a systematic molecular profiling of lung cancers will be conducted by researchers to understand the disease in more depth, and in turn explore novel treatment options in order to better tailor to the needs of different lung cancer patients (Refer to "Lung Cancer Treatment" in Features).

Jumping into the Spotlights section, new data from the PLANET study showed Aflibercept as an effective monotherapy for patients with PCV, an age-related eye disease.

Dr. Anita Damodaran, a scientist from The Pond's Institute, shared a breakthrough finding from their research on the role that inflammation plays in acne pathogenesis, and discovered a new approach to tackle inflammation and reduce acne lesions. She suggested that acne is best treated by taking a holistic approach which includes both dietary/nutrition and topical interventions. If you are seeking career opportunities in the healthcare industry, an interview article with Ms Goh from Roche Diagnostics would be insightful as she shares tips of the trade.

As always, you can access APBN's latest issue online on www.asiabiotech.com. You can also check out our Facebook page @Asia Pacific Biotech News, Instagram @asiabiotech, or follow us on Twitter @asia_biotech.

May APBN be a great companion for you in your free time. Happy New Year.

Thank you.


Carmen, Jia Wen Loh
APBN Editor
You can reach me at jwloh@wspc.com

NEWS CRUNCH  
news Inaugural Asia Summit on Global Health highlights Hong Kong's advantages
news Asia Summit on Global Health (ASGH) 2021 — Shaping a Resilient and Sustainable Future
news TechInnovation 2021 Virtual Exhibition to Showcase Sustainable Energy, Food, and Healthcare Solutions
news A New Approach for Effective Gout Treatment
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen Chan
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2021 World Scientific Publishing Co Pte Ltd  •  Privacy Policy